The non-canonical NF-κB pathway is also aberrantly dysregulated in 10–15% of DLBCL cases due to TRAF2 and TRAF3 mutations [125] and consequently identifies a sub-population of tumours that may be targetable via NIK and/or IKKα. The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.